Physician profile
Daniel Ein
NPI 1225124332
$51,871.92
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $165 · 2021: $51K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols, S.A. | $51,102.77 | 2021 | |
| Glaxosmithkline, LLC. | $227.61 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $212.14 | 2019-2020 | |
| Kaleo, INC. | $75.57 | 2019-2021 | |
| Genentech USA, INC. | $60.40 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $50.37 | 2019-2020 | |
| Alk-Abello, INC | $35.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.76 | 2021 | |
| Shire North American Group INC | $22.47 | 2019 | |
| Genzyme Corporation | $21.06 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.73 | 2019 | |
| Optinose US, INC. | $16.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.